These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 21626815)
1. [The use of akatinol memantine in the residual phase of stroke]. Luk'ianiuk EV; Maliukova NG; Shklovskiĭ VM; Saiadian KhS Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12 Pt 2):28-33. PubMed ID: 21626815 [TBL] [Abstract][Full Text] [Related]
2. [Akatinol memantine in patients with vascular cognitive disorders]. Gudkova AA; Sorokina IB; Iakovlev AA; Guliaeva NV; Gekht AB Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):37-40. PubMed ID: 21311485 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of akatinol memantine in moderate cognitive impairments. Levin OS; Yunishchenko NA; Dudarova MA Neurosci Behav Physiol; 2010 Oct; 40(8):926-33. PubMed ID: 20683775 [TBL] [Abstract][Full Text] [Related]
4. [Akatinol memantine in the therapy of cognitive disorders in Parkinson's disease]. Puzin MN; Krivonos OV; Kozhevnikova ZhV Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(1):26-9. PubMed ID: 17310793 [TBL] [Abstract][Full Text] [Related]
5. [Efficacy of phenotropil in the rehabilitation of stroke patients]. Koval'chuk VV; Skoromets AA; Koval'chuk IV; Stoianova EG; Vysotskaia ML; Melikhova EV; Il'iaĭnen EV Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12 Pt 2):38-40. PubMed ID: 21626817 [TBL] [Abstract][Full Text] [Related]
6. [Neuroprotective potential of akatinol-memantine in ischemic stroke]. Makotrova TA; Trusova NA; Shrader NI; Levin OS Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):82-5. PubMed ID: 23994936 [TBL] [Abstract][Full Text] [Related]
7. [Possibilities for neurorehabilitation in the residual period of stroke]. Selishchev GS Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8 Pt 2):46-8. PubMed ID: 23390655 [TBL] [Abstract][Full Text] [Related]
8. [Efficacy, safety and tolerability of a single dose of akatinol memantine in comparison to two-doses in patients with moderately expressed and moderately severe dementia in Alzheimer's disease]. Kolykhalov IV; Gavrilova SI; Kalyn IaB; Selezneva ND; Fedorova IaB Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(1):35-9. PubMed ID: 22678673 [TBL] [Abstract][Full Text] [Related]
9. [The use of Akatinol Memantine in the treatment of gait disturbances in Parkinson's disease]. Miliukhina IV; Gracheva EV Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(8):27-33. PubMed ID: 32929921 [TBL] [Abstract][Full Text] [Related]
10. Somatosensory evoked potentials as a predictor for functional recovery of the upper limb in patients with stroke. Al-Rawi MA; Hamdan FB; Abdul-Muttalib AK J Stroke Cerebrovasc Dis; 2009; 18(4):262-8. PubMed ID: 19560679 [TBL] [Abstract][Full Text] [Related]
11. [Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia]. Litvinenko IV; Odinak MM; Mogil'naia VI; Perstenev SV Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(10):37-42. PubMed ID: 19008850 [TBL] [Abstract][Full Text] [Related]
12. [The use of cereton in the rehabilitation of patients with hemorrhagic stroke]. Buĭlova TV; Glotova ME; Khalak ME; Vashkevich VV Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(5 Suppl 2):57-61. PubMed ID: 19894302 [TBL] [Abstract][Full Text] [Related]
13. [Akatinol memantin in Alzheimer's disease: clinico-immunological correlates]. Androsova LV; Selezneva ND Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(9):36-8. PubMed ID: 11026134 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy of cytoflavin in patients in the acute ischemic stroke]. Odinak MM; Skvortsova VI; Vozniuk IA; Rumiantseva SA; Stakhovskaia LV; Klocheva EG; Novikova LB; Ianishevskiĭ SN; Golokhvastov SIu; Tsygan NV Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):29-36. PubMed ID: 21311484 [TBL] [Abstract][Full Text] [Related]
15. [Clinical features of the formation and possibilities of treatment of posttraumatic cognitive disturbances]. Litvinenko IV; Emelin AIu; Vorob'ev SV; Lobzin VIu Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):60-6. PubMed ID: 21311490 [TBL] [Abstract][Full Text] [Related]
16. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Görtelmeyer R; Erbler H Arzneimittelforschung; 1992 Jul; 42(7):904-13. PubMed ID: 1418054 [TBL] [Abstract][Full Text] [Related]
17. Does hemispheric lateralization influence functional and cardiovascular outcomes after stroke?: an analysis of placebo-treated patients from prospective acute stroke trials. Fink JN; Frampton CM; Lyden P; Lees KR; Stroke; 2008 Dec; 39(12):3335-40. PubMed ID: 18988910 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Ditzler K Arzneimittelforschung; 1991 Aug; 41(8):773-80. PubMed ID: 1781796 [TBL] [Abstract][Full Text] [Related]
19. Speed of finger tapping as a predictor of functional outcome after unilateral stroke. de Groot-Driessen D; van de Sande P; van Heugten C Arch Phys Med Rehabil; 2006 Jan; 87(1):40-4. PubMed ID: 16401436 [TBL] [Abstract][Full Text] [Related]
20. Effect of memantine in Alzheimer's disease evaluated by visual-evoked potentials to pattern-reversal, motion-onset, and cognitive stimuli. Kubová Z; Kremláček J; Vališ M; Szanyi J; Langrová J; Vít F; Kuba M J Clin Neurophysiol; 2010 Oct; 27(5):334-40. PubMed ID: 20844442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]